This application describes a collaborative research program directed toward a better understanding of the physiology and genetic control of blood components and of their safe and effective use in transfusion therapy. This will be achieved through collaborative, interactive research projects that bring together scientists who utilize a wide range of key technologies. The research will seek a better understanding of the structure and function of the alpha-2 macroglobulin receptor (Project 1), the molecular interactions of fibronectin with collagen, heparin, and the fibronectin receptor (Project 2), the structural basis by which intracellular iron controls the synthesis of ferritin and transferrin receptor (Project 3), the control and potential use of organ-like neovascular structures induced by heparin binding growth factor-1 as a potential means of introducing new genetic information (Project 4), the role of the hepatitis B virus in inducing hepatocellular carcinoma in transgenic mice (Project 5), and the production and characterization of factor VIII fragments in order to assess their potential for therapy of factor VIII inhibitor antibodies (Project 6). These projects emphasize the interaction of plasma proteins with cellular receptors, the use of transgenic mice to better characterize the molecular basis of angiogenesis and viral disease pathogenesis, and the use of domains and fragments of plasma proteins in order to better understand their function and to consider their therapeutic applications. These projects will be directed by a group of senior scientists at the Jerome H. Holland Laboratory, a new research facility that has been established by the American Red Cross to provide research and development support for its Blood Service programs. The six research projects will be supported by central, core facilities that prepare monoclonal and polyclonal antibodies (Core B), synthesize peptides and oligonucleotides and carry out protein amino acid and microsequence analysis (Core C), and provide administrative support for the SCOR program (Core A). This SCOR application is based on the contention that the interface of new technologies and interrelated projects will enhance the scientific productivity of these established, independent laboratories.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL044336-03
Application #
3106877
Study Section
Special Emphasis Panel (SRC (EM))
Project Start
1991-01-05
Project End
1995-12-31
Budget Start
1993-01-01
Budget End
1993-12-31
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
American National Red Cross
Department
Type
DUNS #
003255213
City
Washington
State
DC
Country
United States
Zip Code
20006
Healey, J F; Barrow, R T; Tamim, H M et al. (1998) Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 92:3701-9
Sawamoto, Y; Prescott, R; Zhong, D et al. (1998) Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost 79:62-8
Lubin, I M; Healey, J F; Barrow, R T et al. (1997) Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J Biol Chem 272:30191-5
Saenko, E L; Scandella, D (1997) The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem 272:18007-14
Saenko, E L; Shima, M; Gilbert, G E et al. (1996) Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 271:27424-31
Shin, J T; Opalenik, S R; Wehby, J N et al. (1996) Serum-starvation induces the extracellular appearance of FGF-1. Biochim Biophys Acta 1312:27-38
Imamura, T; Friedman, S A; Gamble, S et al. (1995) Identification of the domain within fibroblast growth factor-1 responsible for heparin-dependence. Biochim Biophys Acta 1266:124-30
Scandella, D; Gilbert, G E; Shima, M et al. (1995) Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 86:1811-9
Healey, J F; Lubin, I M; Nakai, H et al. (1995) Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 270:14505-9
Jackson, A; Tarantini, F; Gamble, S et al. (1995) The release of fibroblast growth factor-1 from NIH 3T3 cells in response to temperature involves the function of cysteine residues. J Biol Chem 270:33-6

Showing the most recent 10 out of 38 publications